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Abstract: The new and rapidly advancing field of genomics and related biotechnologies has the ability to either improve or worsen
global health inequities. In general, developing countries are left behind in the development of new technologies and advances in
genomic medicine.
In this view, the University of Toronto Joint Centre for Bioethics (JCB) through the Canadian Program on Genomics and Global
Health has developed 25 research projects on capacity enhancement for developing countries for improving global health equity,
including public health via genomics and related biotechnologies. One project with a great impact was the “Top Ten Biotechnologies
for Improving Health in Developing Countries” for its influence in the “Grand Challenges in Global Health Initiative” foster by the
Melinda Gates Foundation.
Additionally, the UN Millennium Development Project has asked JCB to become the genomics working group for improving global
health through genomics biotechnology and JCB has started by studying applications of genomics/biotechnologies in seven developing
countries: Brazil, China, Cuba, Egypt, India, South Africa and South Korea, which may set examples for other developing nations.
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GENÓMICA, BIOTECNOLOGÍA Y SALUD MUNDIAL: EL TRABAJO DEL CENTRO
ASOCIADO DE BIOÉTICA DE LA UNIVERSIDAD DE TORONTO
Resumen: El nuevo campo de la genómica y sus biotecnologías relacionadas, de rápido desarrollo,  tiene la habilidad tanto de mejorar
como de empeorar las desigualdades globales en salud. En general, los países en desarrollo quedan atrás en el desarrollo de nuevas
tecnologías y avances en la medicina genómica.
En vista de esta situación, el Centro Asociado de Bioética de la Universidad de Toronto (JCB) a través del Programa Canadiense sobre
Genómica y Salud Global ha desarrollado 25 proyectos de investigación sobre desarrollo de capacidades en países en desarrollo para
mejorar la equidad en salud global, incluyendo la salud pública a través de la genómica y sus biotecnologías relacionadas. Entre estos,
un proyecto de gran impacto fue “Diez Biotecnologías de Mayor Importancia para Mejorar la Salud en Países en Desarrollo” por su
influencia en la “Iniciativa sobre los Grandes Desafíos en Salud Global” presentada por la Fundación Bill and Melinda Gates.
Además, el proyecto de las Naciones Unidas “Desarrollos del Milenio” pidió a JCB ser el grupo de trabajo de genómica para la mejora
de la salud global a través de la biotecnología genómica, y JCB ha comenzado estudiando aplicaciones de genómica y biotecnología
en siete países en desarrollo: Brasil, China, Cuba, Egipto, India, Sudáfrica y Sur Corea, que pueden servir de ejemplo para otras
naciones en desarrollo.
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GENÓMICA, BIOTECNOLOGIA E SAÚDE MUNDIAL: O TRABALHO DO CENTRO
ASSOCIADO DE BIOÉTICA DA UNIVERSIDADE DE TORONTO
Resumo: O novo campo da genómica e suas biotecnologías relacionadas, de rápido desenvolvimento,  tem a habilidade tanto de
melhorar como de piorar as desigualdades globais em saúde. Em geral, os países em desenvolvimento ficam atrás no desenvolvimento
de novas tecnologias e avanços na medicina genómica. Em vista desta situação, o Centro Associado de Bioética da Universidade de
Toronto (JCB) através do Programa Canadense sobre Genómica e Saúde Global desenvolveu 25 projetos de pesquisa sobre
desenvolvimento de capacitações em países em desenvolvimento para melhorar a equidade em saúde global, incluindo a saúde pública
através da genómica e suas biotecnologias relacionadas. Entre estes, um projeto de grande impacto foi “Dez Biotecnologías Mais
Importantes para Melhorar a Saúde em Países em Desenvolvimento” por sua influência na “Iniciativa sobre os Grandes Desafios em
Saúde Global” apresentada pela Fundação Bill and Melinda Gates. Alem disso, o projeto das Nações Unidas “Desenvolvimentos do
Milênio” pediu  para que o JCB fosse o grupo de trabalho de genómica para a melhora da saúde global através da biotecnologia
genómica, e o JCB começou estudando aplicações de genómica e biotecnologia em sete países em desenvolvimento: Brasil, China,
Egito, Índia, África do Sul e Coréia do Sul, que podem servir de exemplo para outra nações em desenvolvimento.
Palavras-chave: Genómica, biotecnologia, equidade em saúde global
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Introduction
The year 2003 welcomed the achievement
of two major milestones in genomics. First, it
marked the 50th anniversary of Watson and
Crick’s discovery of DNA, and second, the
completion of the human genome project. How
can all of mankind benefit from these epochal
advances?
In his remarks at the School of Public Health
Leadership Council inaugural meeting, Harvard
University President Larry Summers
highlighted the two most important issues
facing mankind today: first is the health of
people in the developing world, particularly
those in Africa; second is the emerging
revolution in the life sciences which, for the
first time, is providing us with a fundamental
understanding of human nature1.
The University of Toronto Joint Centre for
Bioethics (JCB) has chosen to focus its research
program on addressing these two very issues
through its Canadian Program on Genomics and
Global Health (CPGGH). This is because we
believe that global health inequity is one of the
most important ethical issues facing the world
today. It is evident in the large differences
between life expectancy figures for
industrialized and developing countries. Life
expectancy in Canada is 80 years and rising; in
sub-Saharan Africa, it is 40 years and falling.
Inequities exist in the number of deaths due to
preventable diseases – a figure much higher in
the developing world than in the industrialized
west. There is also a 10//90 gap: only 10% of
public and private health research expenditure
is devoted to the health issues affecting 90% of
the global population2. Most genomics research
also  focuses on health issues affecting the
wealthiest countries in the world(1).
The new and rapidly advancing field of
genomics and related biotechnologies has the
ability to either improve or worsen such
disparities. New technologies and advances in
medicine continue to develop, yet developing
countries continue to be left behind.
In light of this knowledge we were
concerned that, like the information technology
and agricultural biotechnology waves, the
benefits of genomics might not be realized in
developing countries. The potential for such a
“genomics divide” has led us to develop and
propose a strategy for systematically harnessing
genomics to benefit health in the developing
world.3 We have developed a number of
research and capacity enhancement projects
under the umbrella of CPGGH. The program
now has 25 such projects, each designed to
pursue specific goals and objectives with the
ultimate aim of averting a genomics divide and
improving global health equity (Table 1).
Genomics traditionally refers to the study
of all the genes in a person or organism.
However we found this definition to be
operationally inadequate for our research, and
have developed our own definition of genomics
to be the “powerful new wave of health related
life sciences (biotechnologies) energized by the
human genome project and the knowledge and
tools it is spawning (i.e. proteomics,
transcriptomics, metabolomics, etc.)”3.
In this paper we highlight a small number
of the major CPGGH projects. The projects on
the whole aim at improving global health equity,
including public health, via genomics and
1 Summers L. “Remarks of President Lawrence H. Summers,
School of Public Health Leadership Council Inaugural
Meeting.” Cambridge, Massachusetts. October 21, 2003.
2 Global Forum for Health Research. The 10/90 Report on
Health Research 2003-2004. Global Forum for Health
Research; 2004.
3 University of Toronto Joint Centre for Bioethics. Top 10
biotechnologies for improving health in developing countries.
2002. [Website] Available at http://www.utoronto.ca/jcb/
home/news_genomics.htm
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related biotechnologies. A complete list of
program goals, objectives and projects is
available at the CPGGH website4 .
Top 10 Biotechnologies for Improving Health
in Developing Countries
Of the various projects conducted through
the CPGGH to date, the Top 10 Biotechnologies
for Improving Health in Developing Countries
has so far had the greatest global impact. The
project was initiated in response to a report
released by the World Health Organization
(WHO) in April 2002 titled, Genomics and
World Health(2). The WHO report highlighted
the importance of genomics for improving
health in developing countries and, noting the
uncertainty surrounding genomics, suggested
that regular assessments of the relative potential
of these technologies be conducted. These
assessments would then provide researchers,
funding agencies and governments in
developing countries with useful information
to shape policy. The Top 10 Biotechnologies
study is the first to provide this valuable
information. The report is targeted at policy
makers, politicians, educated laypersons and
others who are likely to influence policy and
investment decisions in the health and
biotechnology sectors.
To identify the ten most promising biotech-
nologies, a consensus forming exercise was
conducted as part of a foresight exercise. Fore-
sight exercises have been found to encourage
innovation by increasing communication, en-
couraging long-term thinking, fostering better
coordination between stakeholders and devel-
oping a shared future vision and commitment
to specific goals. In this study, technologies
were identified and ranked by an international
group of 28 eminent scientists with expertise
in biotechnology and global health issues.
Members of this panel were identified through
recommendations of individuals at the World
Health Organization and the Rockefeller Foun-
dation, as well as through literature searches.
Each member was someone well acquainted
with the public health issues of developing
countries. Panelists were encouraged to take a
broad approach in making their suggestions and
to include any biotechnologies, including
genomics, which would be relevant to address-
ing the health problems of the developing
world. Suggestions could include predictive,
preventative, diagnostic and therapeutic tech-
nologies, as well as those convergent between
health and agricultural biotechnology.
To achieve consensus amongst the experts, the
Delphi method was utilized. This structured
process divided the study into three rounds via
emails, faxes, phone calls and personal interviews
over the span of five months. In the first round,
Panelists were asked the question, “What do you
think are the major biotechnologies that can help
improve health in developing countries in the next
five to ten years?” Each panelist was asked for
his or her top three personal choices and
subsequent rounds were used to establish
consensus among their responses. Specific criteria
were not outlined upon initial presentation of the
question in round one; however, as they
responded, panelists were asked to indicate the
criteria upon which their choices were based.
These criteria are briefly outlined in Table 2. The
top 10 biotechnologies (Table 3) are a result of
this structured Delphi methodology and some of
the ten will be discussed briefly below.
Molecular Diagnostics
Infectious diseases are widespread and are
accountable for almost half of all deaths that
occur in developing countries. The diagnostic
tools currently used are often cumbersome,4 Canadian Program in Genomics and Global Health. 2004.
[Website] Available at: www.geneticsethics.net
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expensive and time consuming, and are there-
fore unsuitable for use in developing countries.
Consequently, the Panel ranked “molecular
technologies for affordable, simple diagnostics
of infectious diseases” as the most promising
biotechnology for improving health in the de-
veloping world. Presently, polymerase chain
reaction tests, monoclonal antibodies and re-
combinant antigens are in use or are being tested
in developing countries(3). These tools have
proven to be very accurate and rapid in their
detection of pathogen-associated molecules and
can be modified for use in low-income settings.
As the use of these technologies increases, and
as developing countries begin manufacturing
them, their affordability will increase.
Recombinant Vaccines
Almost half of all deaths in the developing
world are the result of infection due to diseases
such as HIV/AIDS, malaria and tuberculosis. The
Panel therefore recognized the need for effective
vaccines as an approach to preventative medicine
and ranked recombinant vaccines second on the
list. Recombinant vaccines, specifically, refer to
the broad category of vaccines made via DNA
manipulation. A recent study in the Gambia us-
ing a malaria subunit vaccine was shown to pro-
tect 71% of adult men against natural infection(4).
Recombinant technology provides researchers
with greater control over vaccine characteristics
and allows for the production of safer, more ef-
fective, and possibly even less expensive vaccines.
Some recombinant vaccines are already being
manufactured in developing countries, often at a
lower cost than the standard imported alternative.
This technology also introduces the potential for
developing protection against diseases for which
vaccines do not yet exist.
Bioremediation
Bioremediation refers to the use of bacteria
or plants to decontaminate the environment.
Human activity, such as overcrowding, rapid
industrialization and inadequate sanitation, has
contaminated soil, air and water, introducing
major health threats to people in developing
countries. Because of these concerns, the fourth
biotechnology ranked by the Panel is “technolo-
gies for environmental improvement”, such as
bioremediation. At present, the two main types
of pollution threatening human health are or-
ganic waste and heavy metals, both of which
can be detoxified by bacteria. Phytoremedia-
tion, the use of plants to clean up the environ-
ment, is one way in which this technology can
be implemented. Plants have the ability to de-
grade organic pollutants and may be consid-
ered superior to bacteria not only aesthetically
but functionally, as they have the ability to store
significantly large concentrations of toxic met-
als in their tissues.
One of the greatest mass poisonings in his-
tory is that being experienced by Bangladesh
from extensive groundwater arsenic contami-
nation. Between 35 and 77 million people in
the country are at risk and at least 100 000 cases
of debilitating skin lesions are believed to have
already occurred. Recently, a bacterium named
NT-26 was discovered in an Australian gold
mine. This bacterium has the natural ability to
transform arsenite, a soluble form of arsenic,
into arsenate which is much less toxic(5). We
are leading a coalition with Canadian, Austra-
lian, Bangladeshi and American scientists to
sequence and study the bacterial genomes of
bacterium that both convert insoluble arsenic
from the walls of aquifers into soluble arsenic
in water (the cause of the problem) and those
that do the opposite.
Sequencing Pathogen Genomes
The fifth on the list of biotechnologies was
genome sequencing, particularly that of human
pathogens. Using the same technology
employed for the Human Genome Project,
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researchers can sequence the genomics of
pathonogenic microorganisms. Genome
sequence data, most of which is available
online, can be used to develop new vaccines
and drugs.  This information can provide leads
for drug or vaccine development. A group of
Italian researchers discovered numerous
vaccine candidate molecules for a particularly
virulent strain of meningitis using basic
bioinformatics techniques(6). This is just one
of the many examples demonstrating how
genome sequencing can lead to advances in
vaccine development.
Female-Controlled Protection against
Sexually Transmitted Infections (STIs)
The growing global burden  of STIs is
especially devastating to women, who have
little control over safe sex methods such as use
of condoms. There is thus a need for STI
protection for women that is not dependent on
their partner’s consent. Efforts presently
underway include the development of
recombinant vaccines, monoclonal antibodies
and new approaches to the development of
vaginal microbicides. Currently, there is no safe
and effective vaginal microbicide available to
women.  However certain research centres are
working towards such a development. March
2004 marked the beginning of large-scale
efficacy trials for a carrageenan-based product,
the Population Council’s leading microbicide.
These trials come in response to results
collected from several Phase I safety and
acceptability trials that have shown the product
to be well-tolerated in HIV-negative women
from six different countries. Results from Phase
I trials conducted on HIV-negative couples from
Thailand show that the product is also safe for
men. Several characteristics of carrageenan,
such as its ability to remain stable under severe
conditions, increase the suitability of the
microbicide product for use in rural areas with
limited infrastructure. Along with the efficacy
trials underway, Phase I trials on HIV-positive
women and men have also begun(7).
Nutritionally Enriched Genetically Modified
(GM) Crops
With the global population expected to
grow substantially over the next 45 years5 and
with limited global arable land available for
cultivation6, GM crops offer a potential solu-
tion to the expected increase in demand for
healthy food. Malnutrition already affects one
in five people living in developing countries
and leads to increased disease susceptibility,
impaired cognitive and physical development,
and multiple illnesses attributed to specific
nutrient deficiencies. In addressing this issue,
the Panel ranked the use of genetically modi-
fied, nutrient enhanced crops as the eighth
most promising biotechnology. The underly-
ing cause of nutrient deficiency in the devel-
oping world is a diet based primarily on nutri-
ent-poor, staple foods such as rice, potatoes,
corn and cassava. To counter this problem,
several enriched crops have been developed
to date and are under evaluation. An example
is Golden Rice, a strain of rice genetically
engineered to contain increased levels of pro-
vitamin A (ß-kerotene) and iron(8). A large
percentage of the global population depends
on rice as a major food staple making vitamin
A deficiency the leading cause of childhood
blindness and suppressed immune systems in
children of the developing world7. Genetically
5 Population Division of the Department of Economic and
Social Affairs of the United Nations Secretariat. World
Population Prospects: The 2002 Revision. [Website]
Available at: http://esa.un.org/unpp Accessed July 23, 2004.
6 Population Action International. Conserving land: population
and sustainable food production. 1995. [Website] Available
at: http://www.cnie.org/pop/conserving/expanded.htm
Accessed July 19, 2004.
7 World Health Organization. Combating Vitamin A
deficiency. 2003. [Website] Available at: http://www.who.int/
nut/vad.htm Accessed June 29, 2004.
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modified crops theoretically could offer a bet-
ter solution than current interventions.
Despite the potential benefits that GM crops
suggest, they require careful safety assessments
prior to being released into the environment. Sev-
eral criticisms have been raised against the use of
GM crops with regards to the dangers they may
pose to the environment and to our bodies, and
that their benefits have been overestimated. How-
ever, researchers may not be limited to genetic
engineering to achieve certain traits in crops. In-
creased knowledge in plant genomics over the past
decade reveals that several plants have desired,
yet dormant, characteristics and it is often pos-
sible to activate these innate abilities. Through
precision/smart breeding that allows researchers
to pinpoint the genes responsible for a given trait
and then make use of traditional breeding tech-
niques such as crossbreeding and tissue culturing
to produce these enhanced plants without any
transgenesis. Early-stage breeding is mainly done
in the laboratory which saves time and money
that would otherwise be spent growing several
generations of plants in a field8.
Ultimately, the top 10 technologies are in-
tended to provide researchers, funding agen-
cies and government bodies with insight into
which genomics-based technologies will likely
bring improved health in the next five to ten
years. Along with providing this sense of di-
rection, the study illustrates the relevance of
the genomics revolution for global health im-
provement. The technologies identified by the
Panel are highly relevant to many of the major
health problems in the developing world and
have the potential to be affordable alternatives
to existing methods of disease prevention, di-
agnosis and therapy.
Grand Challenges in Global Health
One of the impacts of the top 10 biotech-
nologies report was an invitation from the Bill
and Melinda Gates Foundation (BMGF) invit-
ing the JCB to provide methodological support
for the Grand Challenges in Global Health(9)
initiative. In January 2003, the BMGF an-
nounced this $200 million medical research
initiative with the assumption that, with greater
encouragement and funding, researchers would
focus on health problems in the developing
world. A Grand Challenge was defined as “A
scientific or technological innovation that
would remove a critical barrier to solving an
important health problem in the developing
world with a high likelihood of global impact
and feasibility”. An advertising campaign was
launched in May of 2003 eliciting ideas for
Grand Challenges from scientists around the
world. Several submissions were received and
final decisions were ultimately achieved by oral
consensus at a scientific board meeting. The
resulting challenges (Table 4) were then
grouped according to seven-long range goals,
none of which specifically addresses a single
disease.
UN Millennium Development Goals (UN
MDGs)
As part of its commitment to promote
sustained development and to eliminate global
poverty, the United Nations (UN) is dedicated
to achieving the Millennium Development
Goals (Table 5). The goals are part of a global
agenda aimed at reducing poverty, hunger,
disease, illiteracy, environmental degradation
and discrimination against women by the year
20159. The first seven of the eight goals are
8 Manning R. Super Organics. Wired Magazine May 2004.
Issue 12.05. [Website] Available at: http://www.wired.com/
wired/archive/12.05/food.html Accessed June 18, 2004.
9 United Nations Department of Public Information.
Implementing the millennium declaration: The Millennium
Development Goals and the United Nation’s role. October
2002.
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directed at specific objectives in promoting
development and improving lives, while the
eighth goal focuses on developing global
partnerships as a means to achieve the goals.
In order to monitor the progress in achieving
this commitment, a set of targets and indicators
has been generated specific to each goal10.
As part of the Millennium Project, the UN
has established several task forces including the
Science, Technology and Innovation Task Force
for which the JCB was asked to become the
genomics working group. The CPGGH project,
titled Harnessing Genomics and Biotechnology
for the UN MDGs, examines the role of
genomics and related health biotechnologies as
an example of applying science, technology and
innovation (STI) to meet the MDGs and im-
prove global health. Table 6 highlights the cor-
relation that exists between the top 10 biotech-
nologies and the UN MDGs and exemplifies
how biotechnology can be used to provide so-
lutions for the developing world. Despite these
clear implications, these technologies are not
being readily employed by developing coun-
tries. As a result, it is crucial that we work to-
wards achieving widespread global implemen-
tation, wherever appropriate. In light of the
eighth goal, “fostering a global partnership for
promoting development,” we have proposed a
global genomics initiative that will promote
genomics and biotechnology for development.
The initiative proposes involvement of various
sectors such as academia, government, public
interest groups and the media to name a few, in
order to ensure an inclusive nature that would
facilitate collaborative decision making and
minimize the risks associated with introducing
these technologies to selected countries. This
global network model encourages participation
by developing countries to generate nation-spe-
cific initiatives and subsequently build their
capacity to address their unique health is-
sues(10).
In order to harness the benefits of genomics
for improved health care and development, the
developing world needs better access to
genomics knowledge. The global public goods
concept(11) may assist in the transfer of this
knowledge to the South. Genomics has signifi-
cant characteristics as a global public good for
health, as it is non-excludable and non-rival in
its consumption, yet developing countries have
yet to benefit from its full potential. The UN
MDGs provide new opportunities for scientists
to expand their research efforts in order to trans-
fer this genomics knowledge and its applica-
tions to sustain development and reduce pov-
erty in low-income countries.
Health Biotechnology Innovation Systems
A project currently underway at the JCB
involves case studies of national health biotech-
nology innovation systems in seven different
countries. Brazil, China, Cuba, Egypt, India,
South Africa and South Korea are being stud-
ied to assess the factors that have led to the early
successes in each of these countries. The re-
sults will be compared to identify the means
by which these countries have integrated
genomics into their approach to health and de-
velopment. Based on these results, recommen-
dations will be made for potential ways in which
genomics and biotechnology can be harnessed
in other  developing nations.
Examples of Early Applications of
Genomics/Biotechnologies in Developing
Countries
Three countries that have addressed the im-
portance of integrating genomics into their ap-
proach for health care improvements are China,
10 United Nations Statistics Division. Millennium Indicators
Database. 2004. [Website] Available at: http://
millenniumindicators.un.org/unsd/mi/mi_goals.asp
Accessed July 23, 2004.
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Cuba and Mexico. While China became the first
country in the world to approve the production
of a gene therapy, Mexico has recognized the
potential for genomics in addressing public
health issues. Cuba has a vibrant health bio-
technology sector that is closely linked to its
health care sector. Each of these cases is fur-
ther discussed below.
Gene therapy in China
China is an example of a developing coun-
try that is rapidly moving forward in the use of
genomics and related biotechnologies to im-
prove the health of its citizens. China has dem-
onstrated this by being the first country to ap-
prove the commercial production of a gene
therapy. A company called Shenzhen SiBiono
GenTech obtained a drug license from the Food
and Drug Administration of China for its re-
combinant Ad-p53 gene therapy for head and
neck squamous cell carcinoma. This therapy,
which was made available in 2004 under the
commercial name of Genicide, offers the po-
tential for a one-time treatment which is simple
to administer. Additionally, since China is a
highly populated country, it is possible to re-
cruit enough patients to generate statistically
significant results in clinical trials. Although
there are criticisms against the apparent le-
niency of drug regulatory measures in China –
relative to that of the US or Europe – the  fact
that the gene therapy was approved in the coun-
try will likely make the technology more ac-
ceptable, and may stimulate other developing
nations to follow in China’s footsteps(12).
Cuba and Meningitis B Vaccine Development
Despite being a relatively small country with
serious economic difficulties, Cuba has made
significant advances in the field of health bio-
technology. In the 1980s, Cuba was the first
country, internationally, to introduce a menin-
gitis B vaccine. This development was a prod-
uct of local research projects, and came in re-
sponse to a local outbreak of Meningitis B. A
candidate vaccine was introduced in Cuba in
1985 and this coincided with a reduction in the
incidence of this disease. One of Cuba’s more
recent successes is the development of the first
human vaccine with a synthetic antigen. The
vaccine against Haemophilus influenza type B
(Hib) infection, the Cuban vaccine is a much
cheaper and safer product than existing vac-
cines. The strong commitment and involvement
of government bodies, public research institu-
tions, universities and the health system have
all contributed to Cuba’s progress in the health
biotechnology field11.
Mexico’s Genomic Medicine Initiative
In countries such as Mexico, health prob-
lems are a serious financial burden and the need
for new public health measures has been rec-
ognized. Although some developing countries
may decline to invest in the development of new
technologies due to financial limitations, the
potential for economic growth and social wel-
fare from such an investment does exist. In
2003, Mexico launched a plan to develop a ge-
nomic medicine program which would include
the establishment of an Institute of Genomics
Medicine. After three years of preparation,
Mexico’s plans are moving towards the imple-
mentation of a National Platform for Genomics
Medicine, directed by Gerardo Jiménez-
Sánchez(13). Recently,  the Mexican Congress
approved a law to establish the Institute of
Genomics Medicine. The characteristic genetic
structure of the modern Mexican population
suggests that importing genomic-based tech-
nologies developed for other populations is not
11 Thorsteinsdóttir H, Daar AS, Sáenz TW, Singer PA.  Build-
ing a Biopharmaceutical Innovation System in Cuba: Growth
Through Linkages.  In:  Mytelka LK, ed. Building
(bio)pharmaceutical innovation systems in developing coun-
tries. Maastricht, The Netherlands: Institute for New Tech-
nologies (INTECH), United Nations University, in press.
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the answer to meeting the health demands of
Mexicans. Rather, the genomic applications
should be geared at the genetic structures spe-
cific to Mexican people.
What Can Developed Countries do to help?
Earlier this year, the Speech from the Throne
acknowledged Canada as a “knowledge-rich
country” and encouraged greater application of
this knowledge to help address challenges in
the developing world. At present, less than 1%
of the total Canadian annual research and de-
velopment budget is allocated towards target-
ing the health and environment problems in
developing countries. In his response to the
Speech from the Throne, Prime Minister Paul
Martin stated that as a long-term goal, Canada
should “devote no less than 5% of our research
and development investment to a knowledge-
based approach to develop assistance for less
fortunate countries”12 . The challenge is for
other rich developed countries to emulate the
example set by Canada.
Table 1. Canadian Program on Genomics and Global Health Projects
Current Projects
1. Top 10 Biotechnologies for Improving Health in Developing Countries
2. Genomics as a Global Public Good for Health
3. Harnessing Genomics and Biotechnology for the UN Millennium Development Goals (UNMDGs)
4. Global Genomics Initiative (GGI): Building a Public Dialogue
5. Genome Innovation Systems in Developing Countries
6. Bioscience Business Ethics
7. Ethical Guidelines for Nutrigenomics
8. Ethical Guidelines for Plant-Made Pharmaceuticals
9. Genetically Modified Animals
10. International Comparative Perspectives on Regulation of Genomics Research and on the Implications of Genetic
Testing on Health Systems and Insurance
11. Regulation of Convergent Biotechnology
12. Intellectual Property Modeling Group (IPMG)
13. Regenerative Medicine
14. Regulatory Models of Genomics and Stem Cells for Developing Countries
15. Genomics and Public Health Policy Executive Course
16. Global Genomics Opinion Leaders’ Network
17. Stem Cell Curricular Module for High Schools
18. Public Engagement in Genomics Through Plays
19. Nanotechnology and Development
20. Science, Technology, Innovation and Foreign Policy: Canada’s Role
Upcoming Projects
21. Pharmacogenomics and Global Health
22. Biotechnology and Human Security
23. Diaspora Options: How Developing Countries Can Benefit From Their Emigrant Populations
24. Developing Country Small and Medium Enterprises
25. Next Generation Vaccines
12 University of Toronto Joint Centre for Bioethics. Energizing
Canadian Foreign Policy through Science & Technology
Innovation: Vision, Benefits, and Policy Goals.
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Table 2. Criteria used by Panel for Selecting Top 10 Biotechnologies
Criteria Description
Impact How much difference will the technology make in improving health?
Appropriateness Will it be affordable, robust and adjustable to health care settings in developing countries,
and will it be socially, culturally and politically acceptable?
Burden Will it address the most pressing health needs?
Feasibility Can it realistically be developed and deployed in a time frame of 5-10 years?
Knowledge Gap Does the technology advance health by creating new knowledge?
Indirect Benefits Does it address issues such as environmental improvement and income generation that
have indirect, positive effects on health?
Reference – Nature genetics article
Table 3. Top 10 Biotechnologies for Improving Health in Developing Countries
Final Biotechnology Final
Ranking Score
1 Modified molecular technologies for affordable, simple diagnosis of infectious diseases 288
2 Recombinant technologies to develop vaccines against infectious diseases 262
3 Technologies for more efficient drug and vaccine delivery systems 245
4 Technologies for environmental improvement (sanitation, clean water, bioremediation) 193
5 Sequencing pathogen genomes to understand their biology and to identify new antimicrobials 180
6 Female-controlled protection against sexually transmitted diseases, both with and without
contraceptive effect 171
7 Bioinformatics to identify drug targets and to examine pathogen-host interactions 168
8 Genetically modified crops with increased nutrients to counter specific deficiencies 159
9 Recombinant technology to make therapeutic products (e.g. insulin, interferons) 155
10 Combinatorial chemistry for drug discovery 129
Reference – top 10 report
Table 4. Goals and Grand Challenges
To improve childhood vaccines:
GC 1: Create effective single-dose vaccines that can be used soon after birth;
GC 2: Prepare vaccines that do not require refrigeration;
GC 3: Develop needle-free delivery systems for vaccines.
To create new vaccines:
GC 4: Devise reliable tests in model systems to evaluate live attenuated vaccines;
GC 5: Solve how to design antigens for effective, protective immunity;
GC 6: Learn which immunological responses provide protective immunity.
To control insects that transmit agents of disease:
GC 7: Develop a genetic strategy to deplete or incapacitate a disease-transmitting insect population;
GC 8: Develop a chemical strategy to deplete or incapacitate a disease-transmitting insect population.
To improve nutrition to promote health:
GC 9: Create a full range of optimal bioavailable nutrients in a single staple plant species.
To improve drug treatment of infectious diseases:
GC 10: Discover drugs and delivery systems that minimize the likelihood of drug-resistant microorganisms.
To cure latent and chronic infections:
GC 11: Create therapies that can cure latent infections;
GC 12: Create immunological methods that can cure chronic infections.
To measure disease and health status accurately and economically in poor countries:
GC 13: Develop technologies that permit quantitative assessment of population health status;
GC 14: Develop technologies that allow assessment of individuals for multiple conditions or pathogens at point-of-care.
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Table 5. United Nations Millennium Development Goals
1. Eradicate extreme poverty and hunger
2. Achieve universal primary education
3. Promote gender equality and empower women
4. Reduce child mortality
5. Improve maternal health
6. Combat HIV/AIDS, malaria and other diseases
7. Ensure environmental sustainability
8. Develop a global partnership for development
Combat
infectious
diseases
Reduce child
mortality
Improve maternal
health
Molecular
diagnostics
Early detection, timely
intervention
Helps prevent spread of infection
Avoids waste of resources on
inappropriate treatments
Dipstick assay for the detection
of Salmonella typhi-specific IgM
antibodies. Same-day results,
small volume of serum needed,
stability of reagents and
simplicity of assay allow use in
absence of laboratory facilities.
(Hatta et al UN article)
Recombinant
vaccines
Reduced risk compared with
attenuated vaccines
Rational vaccine design
Malaria subunit vaccine RTS,S
(with AS02 adjuvent) in phase 3
clinical trials in children in
Mozambique.
Improved methods of
vaccine delivery
Needle-free technologies reduce
need for trained personnel, risk of
HIV infection
Controlled release systems help
overcome noncompliance
Heat-stability eliminates need for
refrigeration
Temperature-stable, controlled-
release formulations of synthetic
peptide analog of hepatitis B
antigen and trehalose ester
derivatives.
Sequencing of the
genomes of
pathogens and their
vectors
Boosts search for novel drugs and
vaccines
Improves understanding of
disease mechanism
Ten strains of West Nile disease
vector Culex pipiens, one strain
of malaria-carrying Anopheles
gambiae have same point
mutation in acetylcholinesterase
for insecticide resistance.
Recombinant
proteins
Synthesis by transgenic plants
and animals potentially cheaper
than mammalian cell cultures
Cheaper biosynthesis of
antimalarial artemisin by
Escherichia coli engineered to
express yeast mevalonate
isoprenoid pathway proteins.
Table 6. Mapping the Top Ten Biotechnologies onto the Millennium Development Goals
MDGs Technology Advantages Examples
Combinatorial
chemistry
Rapid generation of many
varieties of chemical compounds
Increased efficiency, potentially
lower costs, fewer by-products
Two new classes of drugs inhibit
Leishmania mexicana cysteine
protease, found from
combinatorial library of 150,000
compounds.
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